Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations. Arvinas on ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Investing.com -- Shares of Arvinas Inc (NASDAQ: ARVN) climbed 1.6% while Pfizer Inc (NYSE: PFE) edged up 0.5% following the announcement of a New Drug Application (NDA) submission to the U.S. Food ...

In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

H.C. Wainwright analyst Andrew Fein notes that Arvinas (ARVN) shared the final data from the VERITAC-2 trial, which the firm sees positioning ...

According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...

Fintel reports that on June 2, 2025, Leerink Partners downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...